Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Researchers identify key factors for successful donor lymphocyte infusion in AML patients

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.

24 Jan 2025

Mapping the human virome to improve disease prevention and treatment

You, my friend, are what scientists call a "holobiont"- an organism made up of human cells and the multiplicity of microscopic species living inside you and on your body.

24 Jan 2025

$2.5 Million Grant Awarded to Indiana University School of Medicine, Beckman Coulter Life Sciences to Expand Leukemia and Lymphoma Testing in Africa

Beckman Coulter and Indiana University receive a $2.5 million grant to expand leukemia and lymphoma testing in Western Kenya, boosting early diagnosis efforts.

From Beckman Coulter Life Sciences - Flow Cytometry 22 Jan 2025

Inflammasome proteins found to prevent cancer by regulating stem cells

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, according to a preclinical study by Weill Cornell Medicine investigators.

17 Jan 2025

Drug in breast cancer trials shows potential for treating blood cancers

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

16 Jan 2025

CAR-NK cells offer safer, more accessible treatment for lymphoma

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to patients.

15 Jan 2025

A new strategy for enhancing the production of protein-based drugs

An international team of researchers led by the University of California San Diego has developed a new strategy to enhance pharmaceutical production in Chinese hamster ovary (CHO) cells, which are commonly used to manufacture protein-based drugs for treating cancer, autoimmune diseases and much more.

15 Jan 2025

Inflammasome protects stem cells from becoming cancerous

13 Jan 2025

Breakthrough microscopy technique reveals how antibodies target cancer cells

In blood cancers such as chronic lymphocytic leukaemia, B cells of the immune system multiply uncontrollably.

10 Jan 2025

New guidelines developed to assist with the management of blood cancers in pregnancy

A new set of guidelines has been developed to assist with the diagnosis and expert management of serious blood cancers in pregnancy.

3 Jan 2025

CAR-T cells carry memory of past antigen encounters

Researchers at the University of Colorado Anschutz Medical Campus have discovered that some CAR-T cells engineered to fight cancer and other conditions carry the memory of past encounters with bacteria, viruses and other antigens within them, a finding that may allow scientists to manufacture the cells in more precise and targeted ways.

2 Jan 2025

LGBTQ+ people relive old traumas as they age on their own

Bill Hall, 71, has been fighting for his life for 38 years. These days, he's feeling worn out.

24 Dec 2024

Scientists discover key protein that helps cancer cells evade CAR T cell therapy

Scientists at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, have collared a tricky culprit that helps cancer cells evade CAR T cell therapy.

17 Dec 2024

Nutrient metabolism regulates T cell exhaustion and therapy potential

Findings reveal that metabolic enzymes ACSS2 and ACLY regulate T cell exhaustion, linking nutrient metabolism to epigenetic changes in immunity.

17 Dec 2024

Scientists create blood test to enhance cancer treatment effectiveness

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Modified chemotherapy regimen for Hodgkin lymphoma reduces long-term side effects

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that can result from treatment, according to researchers in Cambridge.

11 Dec 2024

High-dose chemotherapy followed by autologous stem cell transplant ineffective for patients with mantle cell lymphoma

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following their initial treatment.

11 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.